April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Cytomegalovirus Retinitis Incidence in the Highly Active Antiretroviral Therapy (HAART) Era
Author Affiliations & Notes
  • Elizabeth A. Sugar
    Epidemiology, Biostatistics,
    Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
  • Douglas A. Jabs
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • Alka Ahuja
    Epidemiology,
    Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
  • Jennifer E. Thorne
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • Ronald P. Danis
    Ophthal & Vis Sciences, Univ of Wisconsin-Madison, Madison, Wisconsin
  • Curtis L. Meinert
    Epidemiology,
    Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
  • Studies of the Ocular Complications of AIDS Research Group
    Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland
  • Footnotes
    Commercial Relationships  Elizabeth A. Sugar, None; Douglas A. Jabs, Abbott Laboratories (C), Alcon Laboratories (C), Alergan Pharmaceutical Corporation (C), Applied Genetic Technologies Corporation (C), Corcep (C), Genentech (C), Genzyme Corporation (C), GlaxoSmithKline (C), Heron Evidence Development Ltd (C), Novartis Pharmaceuticals Corporation (C), Roche (C); Alka Ahuja, None; Jennifer E. Thorne, Allergan Pharmaceutical Corporation (C), Heron Evidence Development Ltd (C); Ronald P. Danis, None; Curtis L. Meinert, None
  • Footnotes
    Support  Supported by NEI Cooperative agreements: U10 EY08057, U10 EY08052, U10 EY08067
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4267. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth A. Sugar, Douglas A. Jabs, Alka Ahuja, Jennifer E. Thorne, Ronald P. Danis, Curtis L. Meinert, Studies of the Ocular Complications of AIDS Research Group; Cytomegalovirus Retinitis Incidence in the Highly Active Antiretroviral Therapy (HAART) Era. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4267.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Cytomegalovirus retinitis (CMVR) is among the most common ocular opportunistic infections for patients with AIDS. Prior to the availability of effective anti-retroviral therapy, approximately 30% of patients with AIDS developed CMVR during their lifetime, 25% within 4 years of diagnosis with AIDS. Our goal is to document the incidence and risk factors for CMVR in the era of highly active antiretroviral therapy (HAART) based upon patients with AIDS in the Longitudinal Study of Ocular Complications of AIDS (LSOCA) cohort.

Methods: : Disease history, laboratory testing (CD4+ and CD8+ T cell counts, HIV viral load), and ophthalmologic exams were obtained every six months. Cox proportional hazards models were used to compare risk factors for incidence.

Results: : In the HAART era, the incidence rate for CMVR was 0.35/100 person years (PY) and for individuals or individuals with a CD4+ T cell count below 50 cells/µL at the prior visit, the rate was 3.84/100 PY, a significant increase (p < 0.01). Additional factors associated with increased risk included CD8+ T cell counts below 400 cells/µL (HR: 14, p < 0.01), HIV viral load > 10,000 copies/mL (HR: 38, p < 0.01), presence of HIV retinopathy (HR: 10, p < 0.01), and Karnofsky score < 80 (HR: 2, p = 0.04).

Conclusions: : In the HAART era, patients with AIDS remain at risk for developing CMVR. This risk is significantly higher for those with low CD4+ T cell counts. However, the rate is much lower than the rate observed in the pre-HAART era.

Keywords: retinitis • clinical (human) or epidemiologic studies: prevalence/incidence • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×